In 2017, Ridker et al. reported that administering 150 mg of canakinumab every three months significantly lowered the risk of recurrent cardiovascular events compared to placebo in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS).46 The CANTOS study was groundbreaking, being the first large-scale trial to show that targeting interleukin-1β (IL-1β) with anti-inflammatory treatment significantly reduces cardiovascular events in coronary heart disease patients. The gene discussed is IL1B; the disease is coronary artery disorder.